Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Pharmaceutical company Eli Lilly ... it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Eli Lilly (NYSE: LLY ... but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly. Let's look deeper into the pharmaceutical ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. Stream Connecticut News for free, 24/7, wherever you are. The Danish drugmaker on ...

Eli Lilly's oral GLP-1 medicine aced a phase ... but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly.